In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Seres Therapeutics, with a price target of $14.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
John Newman’s rating is based on several promising developments at Seres Therapeutics. The submission of the Phase 2 study protocol for SER-155 to the FDA is a significant step, with the potential for a quick interim result following the trial’s initiation. This study aims to prevent bloodstream infections in allogeneic transplant patients, which could be a crucial advancement in the field.
Additionally, Seres is actively seeking strategic partnerships, which could include mergers, acquisitions, or funding for their SER-155 program. The company’s collaboration with MSKCC to explore SER-155’s potential in treating immune checkpoint related enterocolitis further demonstrates its commitment to expanding its therapeutic applications. With a solid cash position and anticipated payments from Nestle, Seres is well-positioned financially to support its initiatives, justifying the Buy rating and a price target of $14.